Search Results

About two months into CEO Belén Garijo’s new tenure, Sanofi’s R&D chief has departed, with Xaira’s chief medical officer set to take charge of the pharma’s pipeline.

A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.

Dipharma Francis S.r.l. proudly announced that Dipharma Inc., its US facility located in Kalamazoo, MI, has been inspected by the U.S. Food and Drug Administration and has received the Establishment Inspection Report, satisfactorily closing the inspection process.

Successful completion of GLP toxicology analysis for the intravenous administration of Rutherrin(R) lays the groundwork for regulatory submissions supporting first-in-human clinical development for multiple life-threatening cancers

Dipharma Francis S.r.l. announced the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan, in the North of Italy.

Dipharma Francis S.r.l. announced the completion of the second phase of expansion of its American site, Dipharma Inc., located in Kalamazoo, MI.

Dipharma Francis S.r.l., a leading Contract Development and Manufacturing Organization and a global manufacturer of Active Pharmaceutical Ingredients, announced another new production site of the Group, thefacility located in Caronno Pertusella, near Milan, has received the Good Manufacturing Practice certification - CBPF - from the Regulatory Authority of Brazil, ANVISA.